AstraZeneca: Imfinzi + chemo doubled OS at three years for patients with BTC

Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI or durvalumab, in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival OS benefit at three years for patients with advanced biliary tract cancer, BTC. These results from TOPAZ-1, which are the longest survival follow-up ever reported for a global, randomized Phase III trial in this setting, will be presented on April 18 at the 2024 Cholangiocarcinoma Foundation Conference in Salt Lake City, Utah. .. Stacie Lindsey, CEO, Cholangiocarcinoma Foundation said: “AstraZeneca’s longer survival data in advanced biliary tract cancer represents a meaningful milestone in that we are seeing three-year survival data for the first time for these patients. The data spurs hope that research will continue to improve outcomes for patients living with these challenging and rare cancers.”